Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer
Completed
Phase II trial to study the effectiveness of combining bortezomib with gemcitabine and carboplatin in treating patients who have advanced or recurrent non-small cell lung cancer that has not been previously treated with chemotherapy. Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Bortezomib may al... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2013
Locations: Southwest Oncology Group, San Antonio, Texas
Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
Completed
Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining chemotherapy with a monoclonal antibody may kill more tumor cells. This randomized phase II/III trial is to see if combination chemotherapy w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2013
Locations: Eastern Cooperative Oncology Group, Boston, Massachusetts
Conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
Completed
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kil... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
02/26/2013
Locations: M.D. Anderson Cancer Center at University of Texas, Houston, Texas
Conditions: Head and Neck Cancer
A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
Terminated
This is a parallel arm study to evaluate AGS-8M4 administered in combination with chemotherapy in subjects with ovarian cancer. AGS-8M4 will be administered as an IV infusion until disease worsens.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/26/2013
Locations: Not set, Duarte, California
Conditions: Carcinoma, Ovarian Cancer, Ovarian Diseases, Ovarian Neoplasms
Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer
Completed
The goal of this clinical research study is to find out if giving azacitidine with valproic acid plus carboplatin can help control advanced cancer. The safety of this treatment will be studied as well. Researchers will also collect some extra blood samples for molecular marker studies (studies that may help researchers predict how participants respond to the combined therapy). There were to be two phases of this study: a Phase 1 portion to find acceptable doses of the study drug combination, an... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/19/2013
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumors
S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus filgrastim in treating pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2013
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +84 locations
Conditions: Lung Cancer
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of amifostine, carboplatin and cyclophosphamide, followed by peripheral stem cell transplantation, in treating patients with epithelial ovarian cancer or primary peritone... Read More
Gender:
FEMALE
Ages:
65 years and below
Trial Updated:
02/08/2013
Locations: University of Chicago Cancer Research Center, Chicago, Illinois
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
Completed
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy before surgery may may shrink the tumor so that it can be removed. PURPOSE: This ph... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2013
Locations: University of Chicago Cancer Research Center, Chicago, Illinois +1 locations
Conditions: Lung Cancer
Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Completed
Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of combining bortezomib with carboplatin and etoposide in treating patients who have advanced solid tumors that have not responded to previous treatment
Gender:
ALL
Ages:
16 years and above
Trial Updated:
02/06/2013
Locations: University of Colorado, Denver, Colorado
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors
Completed
The purpose of this study is to determine the maximum tolerated dose (MTD) and to explore the safety and anti-tumor activity of E7389 in combination with carboplatin in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2013
Locations: Not set, New Brunswick, New Jersey +10 locations
Conditions: Cancer
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
Completed
This phase I trial is studying the side effects and best dose of vorinostat when given together with paclitaxel and carboplatin in treating patients with advanced or refractory solid tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat toge... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2013
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether receiving paclitaxel and carboplatin with epirubicin is more effective than paclitaxel and carboplatin alone for ovarian epithelial, fallopian tube, or peritoneal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel and carboplatin with or without epirubicin in treating patients who have stage IIB, stage III, or sta... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/01/2013
Locations: St. Mary's/Duluth Clinic Cancer Center, Duluth, Minnesota +17 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer